Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Neuren Pharmaceuticals Limited ( (AU:NEU) ) has shared an update.
Neuren Pharmaceuticals reported 2025 royalty income of A$65 million from Rett syndrome drug DAYBUE, up 15% year on year, and a profit after tax of A$30 million, with cash and short-term investments rising to A$296 million. Although profit declined versus 2024 due to the absence of prior one-off milestone and voucher revenues, the company has generated A$510 million in cumulative DAYBUE income since its 2023 launch and completed a A$50 million share buy-back, with a new program starting in March 2026.
Commercial momentum for DAYBUE continued, with 2025 net sales of US$391 million and the U.S. launch of new powder formulation DAYBUE STIX, while partner Acadia is targeting further sales growth that would lift Neuren’s royalty take in 2026. Strategically, Neuren advanced its NNZ-2591 pipeline, initiating the Koala Phase 3 trial in Phelan-McDermid syndrome, securing Fast Track designation and patent protection in Pitt Hopkins syndrome, adding SYNGAP-1 related disorder and hypoxic ischemic encephalopathy to development, and positioning itself to potentially benefit from the reauthorised U.S. Rare Pediatric Disease priority review voucher program.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$27.00 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited is an Australian biopharmaceutical company focused on developing therapies for serious neurological disorders, particularly rare pediatric and neurodevelopmental conditions. Its key commercial asset is DAYBUE (trofinetide) for Rett syndrome, partnered with Acadia in North America, while lead pipeline candidate NNZ-2591 targets multiple genetic neurodevelopmental syndromes across global markets.
Average Trading Volume: 367,864
Technical Sentiment Signal: Sell
Current Market Cap: A$1.55B
For an in-depth examination of NEU stock, go to TipRanks’ Overview page.